Christian Arsov
YOU?
Author Swipe
View article: Value of Additional Systematic Cores During Magnetic Resonance Imaging–guided Targeted Biopsy in Prostate Cancer Screening for Young Men: Results from the PROBASE Trial
Value of Additional Systematic Cores During Magnetic Resonance Imaging–guided Targeted Biopsy in Prostate Cancer Screening for Young Men: Results from the PROBASE Trial Open
We looked at the effectiveness of systematic biopsy (usually 12 cores taken from the prostate gland) and targeted biopsy (cores from a suspicious area seen on a scan) of the prostate among men aged 45-54 years as part of a prostate cancer …
View article: Do We Need Early Detection of Grade Group 2 Prostate Cancer in a Screening Program for Young Men? Results from the PROBASE Screening Trial
Do We Need Early Detection of Grade Group 2 Prostate Cancer in a Screening Program for Young Men? Results from the PROBASE Screening Trial Open
In general, low-risk and favorable intermediate-risk prostate cancers (PCs; International Society of Urological Pathology grade group [GG] 1 and GG 2) are slow-growing cancers with low metastatic potential. Active surveillance is recommend…
View article: Prostate Cancer Detection in Younger Men: A Comparative Analysis of Systematic and Magnetic Resonance Imaging–targeted Biopsy in the PROBASE Trial
Prostate Cancer Detection in Younger Men: A Comparative Analysis of Systematic and Magnetic Resonance Imaging–targeted Biopsy in the PROBASE Trial Open
The optimal approach for prostate cancer (PC) screening, including the ideal starting age and most effective diagnostic method, remains under investigation. We evaluated the diagnostic performance of magnetic resonance imaging (MRI)-target…
View article: Worry about prostate cancer and risk perception among middle-aged men: results from the PROBASE trial
Worry about prostate cancer and risk perception among middle-aged men: results from the PROBASE trial Open
Cancer worry and risk perception are relevant psychological factors that influence preventive health behaviors. Therefore, a thorough understanding of the factors that impact their occurrence and manifestation is critical. The objective of…
View article: Risk-adjusted Screening for Prostate Cancer—Defining the Low-risk Group by Data from the PROBASE Trial
Risk-adjusted Screening for Prostate Cancer—Defining the Low-risk Group by Data from the PROBASE Trial Open
The PROBASE study showed that men with baseline prostate-specific antigen (PSA) <1.5 ng/ml at age 45 yr have a very low prostate cancer detection rate over 5 yr and do not need PSA retesting during this time.
View article: MRI in-bore biopsy following MRI/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer
MRI in-bore biopsy following MRI/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer Open
For a relevant proportion of patients with PI-RADS category 4 or 5 and negative or inconclusive findings on previous FB, but with persistent suspicion of csPC, a subsequent IB verified the presence of csPC. Therefore, IB can be a backup in…
View article: Magnetic Resonance Imaging-guided Active Surveillance Without Annual Rebiopsy in Patients with Grade Group 1 or 2 Prostate Cancer: The Prospective PROMM-AS Study
Magnetic Resonance Imaging-guided Active Surveillance Without Annual Rebiopsy in Patients with Grade Group 1 or 2 Prostate Cancer: The Prospective PROMM-AS Study Open
We investigated whether MRI (magnetic resonance imaging) scores can be used to guide whether patients with lower-risk prostate cancer who are on active surveillance (AS) need to undergo repeat biopsies. Follow-up biopsy was deferred for 1 …
View article: Supplementary Tables 1 - 8, Figures 1 - 7 from Hypermethylation of the <i>GABRE∼miR-452∼miR-224</i> Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy
Supplementary Tables 1 - 8, Figures 1 - 7 from Hypermethylation of the <i>GABRE∼miR-452∼miR-224</i> Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy Open
Supplemental Materials Part A: Supplementary Tables and Figures Part B: Supplementary Methods Supplementary Table S1. Clinicopathological characteristics of non-malignant and prostate cancer tissue samples used for bisulfite sequencing, Il…
View article: Supplementary Tables 1 - 8, Figures 1 - 7 from Hypermethylation of the <i>GABRE∼miR-452∼miR-224</i> Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy
Supplementary Tables 1 - 8, Figures 1 - 7 from Hypermethylation of the <i>GABRE∼miR-452∼miR-224</i> Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy Open
Supplemental Materials Part A: Supplementary Tables and Figures Part B: Supplementary Methods Supplementary Table S1. Clinicopathological characteristics of non-malignant and prostate cancer tissue samples used for bisulfite sequencing, Il…
View article: Data from Hypermethylation of the <i>GABRE∼miR-452∼miR-224</i> Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy
Data from Hypermethylation of the <i>GABRE∼miR-452∼miR-224</i> Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy Open
Purpose: Available tools for prostate cancer diagnosis and prognosis are suboptimal and novel biomarkers are urgently needed. Here, we investigated the regulation and biomarker potential of the GABRE∼miR-452∼miR-224 genomic locus.Experimen…
View article: Data from Hypermethylation of the <i>GABRE∼miR-452∼miR-224</i> Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy
Data from Hypermethylation of the <i>GABRE∼miR-452∼miR-224</i> Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy Open
Purpose: Available tools for prostate cancer diagnosis and prognosis are suboptimal and novel biomarkers are urgently needed. Here, we investigated the regulation and biomarker potential of the GABRE∼miR-452∼miR-224 genomic locus.Experimen…
View article: Data on the detection of clinically significant prostate cancer by magnetic resonance imaging (MRI)-guided targeted and systematic biopsy
Data on the detection of clinically significant prostate cancer by magnetic resonance imaging (MRI)-guided targeted and systematic biopsy Open
This is a data article from the original publication "Reasons for missing clinically significant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion-guided biopsy" [1]. From January 2014 to April 2019 a sample collecti…
View article: Adherence to a risk‐adapted screening strategy for prostate cancer: First results of the <scp>PROBASE</scp> trial
Adherence to a risk‐adapted screening strategy for prostate cancer: First results of the <span>PROBASE</span> trial Open
PROBASE is a population‐based, randomized trial of 46 495 German men recruited at age 45 to compare effects of risk‐adapted prostate cancer (PCa) screening starting either immediately at age 45, or at a deferred age of 50 years. Based on p…
View article: Data on the detection of clinically significant prostate cancer by magnetic resonance imaging (MRI)-guided targeted and systematic biopsy
Data on the detection of clinically significant prostate cancer by magnetic resonance imaging (MRI)-guided targeted and systematic biopsy Open
This is a dataset from the original publication “Reasons for missing clinically significant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion-guided biopsy”. From 01/2014 to 04/2019 a sample collective of 785 patient…
View article: Data on the detection of clinically significant prostate cancer by magnetic resonance imaging (MRI)-guided targeted and systematic biopsy
Data on the detection of clinically significant prostate cancer by magnetic resonance imaging (MRI)-guided targeted and systematic biopsy Open
This is a dataset from the original publication “Reasons for missing clinically significant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion-guided biopsy”. From 01/2014 to 04/2019 a sample collective of 785 patient…
View article: Value of T<sub>2</sub> Mapping MRI for Prostate Cancer Detection and Classification
Value of T<sub>2</sub> Mapping MRI for Prostate Cancer Detection and Classification Open
ROI Measurements of benign tissue in the peripheral zone (PZ; purple ROI) and transition zone (TZ; orange ROI), and PCA (red ROI). Quantitative T2 map (A), T2 TSE (B), and calculatedadc map of RS-DWI (C). On Radical prostatectomy (RPE), an…
View article: Pre-operative magnetic resonance imaging can predict prostate cancer with risk for positive surgical margins
Pre-operative magnetic resonance imaging can predict prostate cancer with risk for positive surgical margins Open
Purpose Analysis of patients with pre-operative 3 T multiparametric prostate MRI (mpMRI) to determine reliable MRI-based risk predictors of patients at risk for positive surgical margins (PSM) in robotic assisted radical prostatectomy (RPE…
View article: Arterial input function for quantitative dynamic contrast-enhanced MRI to diagnose prostate cancer
Arterial input function for quantitative dynamic contrast-enhanced MRI to diagnose prostate cancer Open
PURPOSE This study aims to analyze the ability of quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to distinguish between prostate cancer (PCa) and benign lesions in transition zone (TZ) and peripheral zone (PZ) …
View article: A randomized trial of risk‐adapted screening for prostate cancer in young men—Results of the first screening round of the <scp>PROBASE</scp> trial
A randomized trial of risk‐adapted screening for prostate cancer in young men—Results of the first screening round of the <span>PROBASE</span> trial Open
There is no generally accepted screening strategy for prostate cancer (PCa). From February 2014 to December 2019 a randomized trial (PROBASE) recruited 46 642 men at age 45 to determine the efficacy of risk‐adapted prostate‐specific antige…
View article: MRI grading for the prediction of prostate cancer aggressiveness
MRI grading for the prediction of prostate cancer aggressiveness Open
Objectives T o evaluate the value of multiparametric MRI (mpMRI) for the prediction of prostate cancer (PCA) aggressiveness. Methods In this single center cohort study, consecutive patients with histologically confirmed PCA were retrospect…
View article: Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection
Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection Open
Dynamic contrast enhanced imaging (DCE) as an integral part of multiparametric prostate magnet resonance imaging (mpMRI) can be evaluated using qualitative, semi-quantitative, or quantitative assessment methods. Aim of this study is to ana…
View article: Magnetic resonance imaging improves the prediction of tumor staging in localized prostate cancer
Magnetic resonance imaging improves the prediction of tumor staging in localized prostate cancer Open
Objectives The aim of this study was to investigate 3 Tesla multiparametric magnetic resonance imaging (mpMRI)-based predictors for the pretherapeutic T staging of prostate cancer and their accuracy. Methods Consecutive patients with 3 Tes…
View article: Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies
Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies Open
We aimed to investigate the relation between largest lesion diameter, prostate-specific antigen density (PSA-D), age, and the detection of clinically significant prostate cancer (csPCa) using first-time targeted biopsy (TBx) in men with Pr…